Clearside Biomedical Utdelningar och återköp

Utdelning kriterier kontrolleras 0/6

Clearside Biomedical har inte registrerat sig för att betala utdelning.

Viktig information

n/a

Avkastning på utdelning

-216.5%

Återköpsavkastning

Total avkastning till aktieägarna	-216.5%
Framtida utdelningsavkastning	n/a
Utdelningstillväxt	n/a
Nästa utbetalningsdag för utdelning	n/a
Ex utdelningsdag	n/a
Utdelning per aktie	n/a
Utdelningsandel	n/a

Senaste utdelnings- och återköpsuppdateringar

Inga uppdateringar

Recent updates

Uppdatering av berättelse • Dec 15

Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Analysartikel • Jun 24

We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analysartikel • Nov 12

Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Analysartikel • Aug 11

Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)

The analysts covering Clearside Biomedical, Inc. ( NASDAQ:CLSD ) delivered a dose of negativity to shareholders today...

Seeking Alpha • Aug 08

Clearside Biomedical Q2 2022 Earnings Preview

Clearside Biomedical (NASDAQ:CLSD) is scheduled to announce Q2 earnings results on Tuesday, August 9th, before market open. The consensus EPS Estimate is -$0.13 (-18.2% Y/Y) and the consensus Revenue Estimate is $0.3M (-61.5% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 2 downward. Revenue estimates have seen 0 upward revisions and 1 downward.

Seeking Alpha • Apr 13

Clearside Biomedical: A Pivotal 2022 Ahead

XIPERE was officially launched by partner Bausch + Lomb in Q1 2022. CLS-AX cohort 3 has fully enrolled with a fourth cohort to be enrolled Q2 2022 pending safety review of cohort 3. Partner Aura Biosciences will select the route of administration for lead drug candidate AU-011. Clearside is actively seeking gene therapy partners.

Seeking Alpha • Dec 22

Clearside's Safety Data In Wet AMD And Emphasis On SCS Microinjector Make It Great Speculative Play

Clearside Biomedical reported positive safety data from phase 1/2a study using SCS microinjector for suprachoroidal delivery in patients with wet age-related macular degeneration. Clearside Biomedical and its partner Bausch & Lomb received FDA approval of first suprachoroidal injection drug XIPERE for treatment of patients with macular edema associated with uveitis. XIPERE is expected to launch in the 1st half of 2022, and Clearside has already received a $19 million pre-commercial milestone payment for it. Other established pharmaceutical companies exploring the use of the SCS microinjector for suprachoroidal delivery of their eye drugs are REGENXBIO and Aura Biosciences.

Analysartikel • Sep 30

Clearside Biomedical (NASDAQ:CLSD) Is In A Strong Position To Grow Its Business

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Seeking Alpha • Aug 07

Clearside's Value Proposition Is Far From Clear

Clearside is developing treatments for diseases of the suprachoroidal space of the eye. However, even its latest stage asset has very little monetary value. Self-owned programs are in early stages and face stiff competition.

Analysartikel • Jun 17

We Think Clearside Biomedical (NASDAQ:CLSD) Can Easily Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Stabilitet och tillväxt i betalningar

Hämta utdelningsdata

Stabil utdelning: Otillräcklig data för att avgöra om CLSD.Q s utdelningar per aktie har varit stabila tidigare.

Växande utdelning: Otillräcklig data för att avgöra om CLSD.Q s utdelningsbetalningar har ökat.

Utdelningsavkastning jämfört med marknaden

Clearside Biomedical Utdelningsavkastning jämfört med marknaden

Hur är CLSD.Q:s direktavkastning jämfört med marknaden?
Segment	Utdelningsavkastning
Företag (CLSD.Q)	n/a
Marknadens lägsta 25% (US)	1.4%
Marknad Topp 25% (US)	4.3%
Genomsnitt för branschen (Pharmaceuticals)	2.1%
Prognosanalytiker (CLSD.Q) (upp till 3 år)	n/a

Anmärkningsvärd utdelning: Det går inte att utvärdera CLSD.Q s utdelningsavkastning mot de lägsta 25 % av utdelningsbetalarna, eftersom företaget inte har rapporterat några senaste utbetalningar.

Hög utdelning: Det går inte att utvärdera CLSD.Q s utdelningsavkastning mot de översta 25 % av utdelningsbetalarna, eftersom företaget inte har rapporterat några senaste utbetalningar.

Vinstutdelning till aktieägarna

Resultattäckning: Otillräcklig data för att beräkna CLSD.Q s utbetalningskvot för att avgöra om dess utdelningar täcks av intäkter.

Kontantutbetalning till aktieägarna

Kassaflödestäckning: Det går inte att beräkna hållbarheten för utdelningar eftersom CLSD.Q inte har rapporterat några utbetalningar.

Upptäck bolag med stark utdelning

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2026/05/22 21:42
Aktiekurs vid dagens slut	2026/05/22 00:00
Intäkter	2025/09/30
Årlig intjäning	2024/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Clearside Biomedical, Inc. bevakas av 8 analytiker. 0 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
Esther Lannie Hong	Brean Capital Historical (Janney Montgomery)
Debanjana Chatterjee	JonesTrading Institutional Services, LLC
Anupam Rama	J.P. Morgan

Clearside Biomedical Utdelningar och återköp

Utdelning kriterier kontrolleras 0/6

Viktig information

Senaste utdelnings- och återköpsuppdateringar

Recent updates

First Motion for Exclusivity Period Extension Approved For Clearside Biomedical, Inc.

Clearside Biomedical Files Form 15

CLSD.Q: Bankruptcy Sale Process Will Unlock Significant Equity Upside

Clearside Biomedical, Inc. To Be Delisted from Nasdaq

Clearside Biomedical, Inc. Receives Delisting Notice from Nasdaq

Clearside Biomedical, Inc. Filed for Bankruptcy

FDA Alignment And Phase 3 Trials Will Advance AMD Therapy

Clearside Biomedical, Inc. Receives A Non-Compliance Notice from the Listing Qualifications Department of Nasdaq

Clearside Biomedical Receives Staff Determination Letter from Nasdaq Due to Failure to Regain Compliance with the Minimum Bid Price Requirement within the 180-Calendar Day Grace Period

Clearside Biomedical Announces Approval of XIPERE Suprachoroidal Treatment for Uveitic Macular Edema in Canada

Clearside Biomedical, Inc. Announces Reduction in Force

Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting

Clearside Biomedical Data Featured in Six Presentations At Association for Research in Vision and Ophthalmology 2025 Meeting

Clearside Biomedical, Inc. to Report Q1, 2025 Results on May 14, 2025

FDA Alignment And Phase 3 Trials Will Advance AMD Therapy

Clearside Biomedical, Inc., Annual General Meeting, May 30, 2025

Clearside Biomedical, Inc.'s Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit

Clearside Biomedical, Inc. to Report Q4, 2024 Results on Mar 27, 2025

Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD

Clearside Biomedical’S Asia-Pacific Partner, Arctic Vision, Announces Acceptance of Its New Drug Application for Arcatus® for Regulatory Review in China for the Treatment of Uveitic Macular Edema

Clearside Biomedical Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price

Clearside Biomedical Announces Additional Data from the Cls-Ax Oysysy Phase 2B Trial Presented At the Angiogenesis, Exudation, and Degeneration 2025 Meeting

Clearside Biomedical, Inc. Announces Its Asia-Pacific Partner, Arctic Vision, Receives Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore

Clearside Biomedical, Inc. Announces Board Changes

Clearside Biomedical, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Clearside Biomedical, Inc. Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Clearside Biomedical, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Clearside Biomedical's Partner Arctic Vision Reports Positive Topline Results from Phase 3 Clinical Trial of Arcatus for Suprachoroidal Use in Uveitic Macular Edema Patients in China

Clearside Biomedical, Inc. Appoints Dr. Glenn Yiu to Its Scientific Advisory Board

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Clearside Biomedical, Inc. to Report Q1, 2024 Results on May 09, 2024

Clearside Biomedical, Inc., Annual General Meeting, Jun 20, 2024

Insider recently bought US$130k worth of stock

Clearside Biomedical, Inc Appoints Anthony S. Gibney to its Board of Directors

New minor risk - Market cap size

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Clearside Biomedical, Inc. to Report Q4, 2023 Results on Mar 12, 2024

Clearside Biomedical, Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

Clearside Biomedical, Inc. Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Consensus revenue estimates increase by 464%

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Clearside Biomedical, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting

Clearside Biomedical Receives Non-Compliance Notice from Nasdaq

Consensus revenue estimates increase by 362%

New major risk - Revenue and earnings growth

New major risk - Negative shareholders equity

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Clearside Biomedical, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Clearside Biomedical Highlights Excellent Safety Profile of CLS-AX and Potential for Extended Duration of Effect in Data Presentation At the American Society of Retina Specialists 41st Annual Scientific Meeting

Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of Its New Drug Application for Suprachoroidal Use of Arcatus® for the Treatment of Uveitic Macular Edema

We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate

Clearside Biomedical, Inc. Opens Enrollment in Odyssey Phase 2B Clinical Trial of Cls-Ax (Axitinib Injectable Suspension) in Wet AMD

Consensus revenue estimates decrease by 57%

Consensus revenue estimates increase by 100%, EPS downgraded

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Chief Medical Advisor-Retina notifies of intention to sell stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 9.4% to US$5.80

Clearside Biomedical, Inc. Executive Changes, Effective February 17, 2023

Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD

High number of new directors

Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Price target increased to US$7.50

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)

Clearside Biomedical Q2 2022 Earnings Preview

Price target decreased to US$9.00

Consensus revenue estimates fall by 91%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new directors